GSK plc unveiled encouraging results from its pivotal Eagle-1 phase 3 trial for gepotidacin, a potential breakthrough oral antibiotic for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.
The pharma company is evaluating its Paxlovid oral treatment, intended for high-risk patients who have tested positive for the virus, in pediatric subjects.
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
The excipients specialist shares findings from its research into the ins and outs of 3D powder bed printed tablets and how it can benefit drug development.
The pjarmaceutical excipient, intended for use in the formulation of flash orally dissolving tablets, is designed to disintegrate in less than 10 seconds.
A leader from the excipients firm discusses how ODTs appeal to seniors and patients on the go, and the formulation-related challenges with such tablets.
A leader from the manufacturing technology provider talks about how companies can work to streamline oral solid dose manufacturing to remain competitive.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Ferring is the third company in a week which will use Enteris BioPharma’s Peptelligence engineering platform for small molecules to develop oral formulations.
A potential Type 2 diabetes drug from Novo Nordisk has met the primary endpoint of a Phase II trial and shares of Emisphere Technology, which helped to formulate the oral version of semaglutide, jumped by as much as 70% on Friday.
Enteris has secured its first partnership to develop metabolic peptides for Nordic Bioscience using an oral delivery platform it says offers unparalleled bioavailability.
Silicon-based micro-machined devices for the controlled delivery of
oral therapeutics, developed by Tejal Desai from the University of
California, have won first prize at the 2006 Eurand Award
Programme, impressing with their ability...
Drug delivery specialists Merrion Biopharma has announced the
opening of new facilities in Ireland, strengthening its position in
the $24 billion oral drug delivery market and reinforcing the
healthy state of the Irish pharmaceutical...